It is very uncertain whether vitamin D changes cardiovascular death compared with placebo or no treatment (very low certainty).
It is very uncertain whether vitamin D changes graft loss compared with placebo or no treatment (very low certainty).
Bisphosphonate may leads to lower acute graft rejection compared with placebo or no treatment (low certainty).
It is very uncertain whether bisphosphonate changes death (all causes) compared with placebo or no treatment (very low certainty).
It is very uncertain whether bisphosphonate changes cardiovascular death compared with placebo or no treatment (very low certainty).
Bisphosphonate may leads to lower bone pain compared with placebo or no treatment (low certainty).
It is very uncertain whether bisphosphonate changes spinal deformity compared with placebo or no treatment (very low certainty).
It is very uncertain whether bisphosphonate changes hypocalcaemia compared with placebo or no treatment (very low certainty).
It is very uncertain whether vitamin D changes fracture compared with placebo or no treatment (very low certainty).
It is very uncertain whether vitamin D changes acute graft rejection compared with placebo or no treatment (very low certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: RBC transfusions compared with with every two weeks (low certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: hypertension compared with with every two weeks (moderate certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: arteriovenous complications compared with with every two weeks (low certainty).
Epoetin theta showed no clear difference in deaths compared with epoetin beta (low certainty).
Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).
Epoetin theta showed no clear difference in adverse events: RBC transfusions compared with epoetin beta (low certainty).